Netscientific surges as peerreviewed article confirms potential of PDS Biotechs Versamune immunotherapy platform

Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack

More From BioPortfolio on "Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform"